Breaking News Instant updates and real-time market news.

CELG

Celgene

$98.50

-2.13 (-2.12%)

07:50
10/17/16
10/17
07:50
10/17/16
07:50

Celgene data suggests viable drug, says Leerink

Leerink analyst Geoffrey Porges notes that Celgene has announced top-line results from Phase 1b study of GED-301 in Crohn's Disease, and says that absent statistical analyses or a greater insight into participant performance across the study's treatment arms, or longer duration of follow-up, it is difficult to evaluate the full significance of these results. Nonetheless, the analyst believes the drug seems to have some modest efficacy which bodes positively for potential approval as a front-line agent in Crohn's Disease. He reiterates a Market Perform rating on the shares.

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$98.50

-2.13 (-2.12%)

09/29/16
SBSH
09/29/16
NO CHANGE
Target $127
SBSH
Buy
Citi ups Celgene target to $127 on luspatercept opportunity
Citi analyst Robyn Karnauskas raised her price target for Celgene (CELG) to $127 from $124 citing greater confidence in the company's myelodysplastic syndrome and beta thalassemia opportunities. After initiating coverage of Celgene partner Acceleron (XLRN) with a Neutral rating, Karnauskas now sees adjusted peak sales for these indications of $1.7B versus $825M previously. Investors are missing the "not-so-distant catalyst" as Phase 3 luspatercept data in these indications could come in late 2017/early 2018, the analyst tells investors in a research note. She keeps a Buy rating on shares of Celgene.
09/30/16
PIPR
09/30/16
NO CHANGE
Target $25
PIPR
Overweight
Piper's Schimmer found Nektar validation at Celgene event
Piper Jaffray analyst Joshua Schimmer says Celgene's (CELG) analyst event provided "another indirect validation" of Nektar Therapeutics' (NKTR) oncology approach. Celgene surprisingly implicated IL-2 as one of the primary mechanisms of Revlimid, Schimmer tells investors in a research note. He views the development as supporting his "enthusiastic outlook" for NKTR-214, the company's long-acting IL-2 targeting Teffector cells. The analyst reiterates an Overweight rating on Nektar with a $25 price target.
10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.
10/17/16
WELS
10/17/16
NO CHANGE
WELS
Celgene data better than expected, says Wells Fargo
After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

COLD

Americold Realty Trust

20:35
01/18/18
01/18
20:35
01/18/18
20:35
Syndicate
Americold Realty Trust 45.3M share IPO priced at $16.00 »

The company sold 29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HTGM

HTG Molecular

$3.40

0.54 (18.88%)

20:29
01/18/18
01/18
20:29
01/18/18
20:29
Syndicate
HTG Molecular 12M share Secondary priced at $2.90 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

NINE

Nine Energy Services

20:27
01/18/18
01/18
20:27
01/18/18
20:27
Syndicate
Nine Energy Services 7M share IPO priced at $23.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

, STI

SunTrust

$67.94

-0.41 (-0.60%)

20:25
01/18/18
01/18
20:25
01/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

SLB

Schlumberger

$76.37

-0.84 (-1.09%)

STI

SunTrust

$67.94

-0.41 (-0.60%)

SYF

Synchrony

$37.30

-0.76 (-2.00%)

CFG

Citizens Financial

$45.76

-0.08 (-0.17%)

RF

Regions Financial

$18.15

-0.21 (-1.14%)

KSU

Kansas City Southern

$111.50

0.69 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 19

    Jan

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

URGN

UroGen Pharma

$42.46

-0.8 (-1.85%)

19:12
01/18/18
01/18
19:12
01/18/18
19:12
Syndicate
UroGen Pharma 1.463M share Secondary priced at $41.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

ADT

ADT Inc.

19:10
01/18/18
01/18
19:10
01/18/18
19:10
Syndicate
ADT Inc. 105M share IPO priced at $17.00-19.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

18:47
01/18/18
01/18
18:47
01/18/18
18:47
Periodicals
House Freedom Caucus to support bill preventing government shutdown, AP says 

Reference Link

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$279.14

-0.47 (-0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$55.35

-2.54 (-4.39%)

18:39
01/18/18
01/18
18:39
01/18/18
18:39
Periodicals
BNY Mellon to boost wages for 1,000 workers after tax reform, WSJ says »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Mar

TRNC

tronc

$19.23

0.22 (1.16%)

18:28
01/18/18
01/18
18:28
01/18/18
18:28
Periodicals
tronc to investigate LA Times' CEO Ross Levinsohn, Financial Times reports »

tronc has opened an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

18:19
01/18/18
01/18
18:19
01/18/18
18:19
Hot Stocks
IBM's Schroeter says mainframe isn't going away »

IBM senior VP of Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ATR

AptarGroup

$87.24

0.4 (0.46%)

18:16
01/18/18
01/18
18:16
01/18/18
18:16
Hot Stocks
AptarGroup chairman King Harris to retire in May »

AptarGroup chairman of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 27

    Apr

  • 02

    May

  • 27

    Jul

  • 26

    Oct

FULT

Fulton Financial

$18.30

-0.25 (-1.35%)

18:12
01/18/18
01/18
18:12
01/18/18
18:12
Hot Stocks
Fulton Financial to raise its minimum wage to $12 per hour »

Fulton Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SNAP

Snap

$14.01

0.49 (3.62%)

18:03
01/18/18
01/18
18:03
01/18/18
18:03
Periodicals
Snap fires roughly two dozen employees, Cheddar reports »

Snap Inc. has laid off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 06

    Feb

  • 07

    Feb

PAVM

PAVmed

$2.54

-0.02 (-0.78%)

17:57
01/18/18
01/18
17:57
01/18/18
17:57
Syndicate
PAVmed files to sell common stock, no amount given »

Dawson James Securities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PODD

Insulet

$72.89

-0.02 (-0.03%)

, DXCM

Dexcom

$56.28

-0.04 (-0.07%)

17:51
01/18/18
01/18
17:51
01/18/18
17:51
Recommendations
Insulet, Dexcom, TNDM, Medtronic analyst commentary at Piper Jaffray »

Insulet is a favored…

PODD

Insulet

$72.89

-0.02 (-0.03%)

DXCM

Dexcom

$56.28

-0.04 (-0.07%)

TNDM

TNDM

MDT

Medtronic

$87.26

1.15 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 01

    Mar

17:50
01/18/18
01/18
17:50
01/18/18
17:50
General news
Breaking General news story  »

Cleveland Federal Reserve…

IBM

IBM

$169.12

0.47 (0.28%)

17:39
01/18/18
01/18
17:39
01/18/18
17:39
Earnings
Breaking Earnings news story on IBM »

IBM sees FY18 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TTD

Trade Desk

$48.36

-1.12 (-2.26%)

17:38
01/18/18
01/18
17:38
01/18/18
17:38
Initiation
Trade Desk initiated at Stifel »

Trade Desk initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$24.04

-0.52 (-2.12%)

, FB

Facebook

$179.80

2.2 (1.24%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Hot Stocks
Snap user metrics being put into question by Mashable, Muddy Waters »

After the close, Mashable…

TWTR

Twitter

$24.04

-0.52 (-2.12%)

FB

Facebook

$179.80

2.2 (1.24%)

SNAP

Snap

$14.01

0.49 (3.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 23

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

TWTR

Twitter

$24.04

-0.52 (-2.12%)

17:37
01/18/18
01/18
17:37
01/18/18
17:37
Recommendations
Twitter analyst commentary at Stifel »

Twitter coverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Hot Stocks
Breaking Hot Stocks news story on IBM »

IBM sees FY18 free cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

IBM

IBM

$169.12

0.47 (0.28%)

17:36
01/18/18
01/18
17:36
01/18/18
17:36
Earnings
IBM sees Q1 EPS 17%-18% of $13.80 FY expectation, consensus $2.28 »

Says has momentum in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ZG

Zillow

$43.86

-0.49 (-1.10%)

, Z

Zillow

$43.97

-0.57 (-1.28%)

17:33
01/18/18
01/18
17:33
01/18/18
17:33
Downgrade
Zillow, Zillow rating change at Stifel »

Zillow resumed with a…

ZG

Zillow

$43.86

-0.49 (-1.10%)

Z

Zillow

$43.97

-0.57 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

AXP

American Express

$99.86

-0.9 (-0.89%)

, HLT

Hilton

$83.95

-0.08 (-0.10%)

17:30
01/18/18
01/18
17:30
01/18/18
17:30
Hot Stocks
American Express 'excited' about co-brand partnership with Hilton and Marriott »

Says delinquencies will…

AXP

American Express

$99.86

-0.9 (-0.89%)

HLT

Hilton

$83.95

-0.08 (-0.10%)

MAR

Marriott

$141.13

-0.87 (-0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 14

    Feb

  • 15

    Feb

  • 25

    Mar

APRN

Blue Apron

$3.20

0.04 (1.27%)

17:30
01/18/18
01/18
17:30
01/18/18
17:30
Hot Stocks
Breaking Hot Stocks news story on Blue Apron »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.